40 Background: Healthcare disparities in colorectal cancer, driven by insurance status and socioeconomic factors, lead to delayed diagnoses poorer surgical outcomes. We sought examine the impact of on presentation, treatment, in-hospital mortality CRC patients undergoing colectomy using Nationwide Inpatient Sample (NIS) database. Methods: included aged 18-65 years diagnosed with colon cancer colectomy, as identified ICD-9-CM codes, who had private insurance, Medicaid, or no from January 1,...

682 Background: Bladder cancer is the sixth most common malignancy in United States. Recent advances treatment paradigm have changed landscape of bladder cancer. Patient-reported outcome measures (PROMs) are symptom burden and health related quality life (HRQoL) that come directly from patient, without clinician interpretation. PROMs can be intervention and/or a trial. We aimed to evaluate trends usage PROs for patients with muscle invasive (MIBC) locally advanced or metastatic (mBC) as...

678 Background: Bladder cancer is the sixth most common malignancy in United States. Social determinants of health (SDOH) have been increasingly recognized as drivers disparities care. Improved understanding role social vulnerabilities could better inform care delivery interventions towards equitable for bladder patients. We aimed to study impact key SDOH measures (everyday discrimination, supportive relationships, neighborhood characteristics, and food housing security) on perception...

463 Background: Accurately predicting postoperative outcomes, such as major and minor complications, readmissions, mortality, enables personalized preoperative planning, informed decision-making, improved perioperative management. In this study, we utilized a machine learning (ML) model to predict these outcomes in RCC patients undergoing nephroureterectomy, radical nephrectomy, partial other excision procedures on the kidney using data from National Surgical Quality Improvement Program...

347 Background: Patients diagnosed with localized high-risk prostate adenocarcinoma (LHRPC) high Gleason scores (8-10) and prostate-specific antigen (PSA) levels ≤ 4 may experience an altered clinical course. In these patients, low PSA reflect cellular dedifferentiation, indicating more aggressive tumor behavior despite appearing to have a disease burden. We aim investigate the impact of in patients LHRPC better understand prognosis optimize treatment strategies. Methods: included based on...

28 Background: Prostate cancer carries one of the highest burdens racial disparities in outcomes oncology. Understanding social determinants health (SDOH), which measure inequities healthcare, could give us insight into quality improvement strategies. We aimed to study impact key SDOH measures (everyday discrimination, supportive relationships, neighborhood characteristics, and food housing security) on perception overall prostate survivors using a publicly available database. Methods: A...

PURPOSE The European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) and the ASCO Value Framework (ASCO-VF) are tools designed to assess value anticancer therapies. International conferences primary venues sharing trial outcomes, often influencing clinical practices even before full publications available. This analysis compares ESMO-MCBS ASCO-VF in evaluating benefit all phase III trials presented at 2022 Annual Meeting (AM) examine level agreement between these...

Collapsing Glomerulopathy (CG), also known as the collapsing variant of Focal Segmental Glomerulosclerosis (FSGS), is distinct in both its clinical severity and pathophysiologic characteristics from other forms FSGS. This lesion occurs disproportionally patients carrying two APOL1 risk alleles, classic histologic resulting Human Immunodeficiency Virus (HIV) infection podocytes. Other viral infections, including parvovirus B19, drugs such interferon that perturb immune system, have been...

Background: Several rheumatic conditions have been associated with increased risk of malignancies, especially hematopoietic and lymphoproliferative malignancies. Rheumatoid arthritis has a relative 1.5-4 for the development hematological malignancies (HM)1. A variety immunosuppressive immunomodulatory medications also linked to HM2. Moreover, advances in field biologic agents being used treatment diseases (RD), landscape keeps changing. To our knowledge, data on general trends HM as well RD...

12145 Background: Burton tyrosine Kinase inhibitors (BTKi) have revolutionized the care of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHL) – including relapsed/refractory mantle cell, ABC diffuse large B cell lymphoma lymphoplasmacytic lymphoma. Ibrutinib was first BTKi to be approved. The newer covalent include acalabrutinib zanubrutinib, both which are approved for frontline relapsed CLL as well NHL. All these agents cardiovascular adverse events. We aimed assess...

504 Background: Testicular cancer (TC) is a malignancy with five-year survival reaching up to 95%. It estimated that 470 deaths from this disease will occur in the United States 2023. Even exceptional rates, it important recognize need of hospice these patients. Enrollment associated lower healthcare costs, symptom burden, and psychological distress improved quality life. We used publicly available CDC WONDER (Centers for Disease Control Prevention Wide-ranging Online Data Epidemiologic...

Pembrolizumab, a widely used immune checkpoint inhibitor (ICI), has revolutionized the treatment of non-small cell lung cancer (NSCLC). Identifying unique tumor characteristics in patients likely to respond pembrolizumab could help clinical adjudication and development personalized therapeutic strategy. In this retrospective study, we reviewed data pathological features 84 NSCLC treated with pembrolizumab. We examined correlation between demographic histopathologic obtained before...

Jatwani, Karan MD; Kaur, Harsimran MBBS; Chugh, Shraddha MD, FACP, FACR, RhMSUS Author Information

Tumid lupus erythematosus (TLE) is a rare variant of cutaneous erythematosus. Clinically, it lacks typical changes found in discoid and antinuclear antibodies (ANA) levels are elevated only 10% the patients. Coexistent systemic (SLE) has been reported to be rare, literature shows few case reports. We present coexistent tumid SLE. 48-year-old Caucasian female who presented with chronic facial rash, photosensitivity, intermittent oral ulcers, joint pain morning stiffness, unintentional weight...

Article Tools CASE REPORTS OPTIONS & TOOLS Export Citation Track Add To Favorites Rights Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00476 JCO Precision Oncology no. 7 (2023) e2200476. Published online February 21, 2023. PMID: 36809053 Loss of Rb1 Associated With the Onset Acquired Resistance to Trastuzumab Deruxtecan in TP53-/HER2-Mutated Non–Small-Cell Lung Cancer: Case Series Ashish Gupta , MBBS1xAshish GuptaSearch for by this author; Karan...

Bronchiolitis obliterans organising pneumonia as an initial manifestation of systemic lupus erythematosus (SLE) is a rare and uncommon presentation. We describe case SLE presenting with shortness breath, found to have pneumothorax, bilateral nodular infiltrates along pleural effusions pericardial effusion. Work-up suggested diagnosis active anaemia, thrombocytopenia, positive antinuclear antibodies (ANAs) anti-double-stranded DNA. On retrospective review patient records, from 8 years prior...

prevent incorrect diagnosis and treatment, which would improve overall outcomes in HCL remission survival rates.

231 Background: Prostate Cancer (PCa) is the most common cancer in men and second cause of mortality. The identification preferred place death (PPOD) has been shown to improve delivery palliative care, reduce healthcare costs, quality care. We evaluated trends PPOD for patients hospice utilization with PCa USA from 2003 2020 based on CDC WONDER (Centers Disease Control Prevention Wide-ranging Online Data Epidemiologic Research) database. Methods: US nationwide state-level data was pooled...

340 Background: Most patients with high or very risk localized prostate cancer (PCa) experience disease recurrence after radical prostatectomy (RP). A intra-tumoral CD8 + T lymphocyte density is associated improved survival post-RP, 1 suggesting possible clinical benefit from neoadjuvant chemokine modulation (CKM). 2,3 We present the interim results of a three-arm, phase II trial where PCa scheduled to undergo RP were randomized in 1:1:1 ratio 2-week regimen CKM triplet (Arm A: rintatolimod...

580 Background: Bladder Cancer (BC) is associated with significant treatment related morbidity and mortality risk. End of life care (EOL) advance planning are crucial in oncology BC patients. Place Death (PoD) an important determinant patient caregiver preference, access to home-based supportive care, cost caregiving at EOL. We evaluate trends PoD for patients hospice utilization the U.S. from 2003 2020 based on CDC WONDER (Centers Disease Control Prevention Wide-ranging Online Data...

269 Background: Machine learning has shown potential in accurately predicting outcomes after urologic surgery, allowing for improved patient selection, risk stratification, and discharge dispositions. Healthcare disparities pose a major public health challenge, leading to unequal different groups. Successful measures mitigate these rely on precise recognition of the demographic groups impacted. In this study, we utilized AI ML models predict such adverse so that early intervention may lead...